Henlius to Initiate P-III Study of HLX04-O (biosimilar, bevacizumab) in Australia

 Henlius to Initiate P-III Study of HLX04-O (biosimilar, bevacizumab) in Australia

Henlius to Initiate P-III Study of HLX04-O (biosimilar, bevacizumab) in Australia

Shots:

  • Henlius reported that TGA has approved the filing of clinical trial for HLX04-O to treat wet-AMD
  • The two part P-III global study is expected to be initiated in Australia to further evaluate the efficacy & safety of HLX04-O (vitreous injection) in treatment of wAMD
  • HLX04-O is a recombinant anti-VEGF humanized mAb ophthalmic injection and has the potential to be one of the first bevacizumab approved for ophthalmic diseases

Click here ­to­ read full press release/ article | Ref: Henlius | Image: Henlius

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post